美托洛尔对DDD型起搏器治疗三度房室传导阻滞患者心功能及QT间期离散度的影响

doi:10.3969/j.issn.1006-6233.2025.02.030

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1131 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the effect of metoprolol on cardiac function and QT interval dispersion in patients with third-degree atrioventricular block (AVB) treated with a DDD pacemaker. Methods: A retrospective analysis was conducted on the clinical data of patients with third-degree AVB treated with DDD pacemaker in the cardiology department of our hospital from January 2021 to January 2024. Patients who received routine treatment after surgery were included in the control group, while those who received metoprolol in addition to routine treatment were included in the observation group. Both groups were treated for 3 months. Propensity score matching with a 1∶1 nearest neighbor method was used to balance confounding factors, resulting in 63 patients per group. Cardiac function (left atrial diameter [LAD], left ventricular end-diastolic diameter [LVEDD], left ventricular mass index [LVMI]), electrocardiogram data (resting heart rate, average heart rate, QT interval dispersion), cardiac biomarkers (plasma brain natriuretic peptide [BNP], cardiac troponin I [cTnI], creatine kinase-MB[CK-MB]), and adverse reactions during treatment were compared before and 3 months after treatment. Results: After 3 months of treatment, LAD, LVEDD, LVMI, resting heart rate, average heart rate, QT interval dispersion, BNP, cTnI and CK-MB were significantly reduced compared to before treatment in both groups. The differences between the pre- and post-treatment values in the observation group were greater than those in the control group, with statistically significant differences (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups during the treatment period (P>0.05). Conclusion: Metoprolol significantly improves cardiac function and cardiac biomarkers in patients with third-degree AVB treated with DDD pacemaker, optimizes QT interval dispersion, and demonstrates high safety.

Key words： Metoprolol DDD pacemaker Third degree atrioventricular block Cardiac function QT interval dispersion

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Xiao
	PENG Haiyan
	LI Luna

Cite this article:

YANG Xiao,PENG Haiyan,LI Luna. Effect of Metoprolol on Cardiac Function and QT Interval Dispersion in Patients with Third-Degree Atrioventricular Block Treated with DDD Pacemaker[J]. HeBei Med, 2025, 31(2): 339-344.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2025.02.030 OR http://www.hbyxzzs.cn/EN/Y2025/V31/I2/339

[1] 胡华超,陈娴雅,谢思媛,等.心房颤动合并心力衰竭患者的临床特点及治疗现状分析的多中心研究[J].中国全科医学,2023,26(5):541-549.
[2] De Lazzari M,Martini N,Migliore F,et al.Efficacy and safety of isoprenaline during unstable third-degree atrioventricular block[J].Cardiovasc Dev Dis,2023,10(12):475.
[3] 冯莉,李学文,吕吉元,等.三度房室传导阻滞犬血清炎症水平变化及其与左心室功能的相关性研究[J].中华生物医学工程杂志,2023,29(4):415-420.
[4] 刘金玉,王占启,张盼,等.肺栓塞合并三度房室传导阻滞安装起搏器一例[J].中华老年心脑血管病杂志,2023,25(5):537-539.
[5] 张兰芳,陈春红,张晶.矫正型大动脉转位伴三度房室传导阻滞植入DDD起搏器1例[J].中国循证心血管医学杂志,2022,14(1):114-115.
[6] 陈积慈,黄佩花,廖旺,等.美托洛尔联合二丁酰环磷腺苷钙治疗冠心病心力衰竭并心律失常临床研究[J].中国药业,2023,32(10):95-98.
[7] 李志伟,孟强,白冰,等.胺碘酮注射液联合酒石酸美托洛尔治疗冠心病合并快速心房颤动疗效观察[J].创伤与急危重病医学,2022,10(3):199-201,209.
[8] Diamond A,Goldenberg I,Younis A,et al.Effect of carvedilol vs metoprolol on atrial and ventricular arrhythmias among Implantable cardioverter-defibrillator recipients[J].JACC Clin Electrophysiol,2023,9(10):2122-2131.
[9] 向晋涛.DDD起搏模式的散点图[J].中国心脏起搏与心电生理杂志,2022,36(6):570-573.
[10] 蔡吉,肖楠川,张一洁,等.美托洛尔依折麦布联合治疗老年冠心病的疗效及对RAAS的影响[J].河北医学,2023,29(1):167-172.
[11] 马玉娟,姚学旺,卢吉锋.益气养阴复脉颗粒联合酒石酸美托洛尔片治疗室性早搏的疗效与安全性评价[J].世界科学技术-中医药现代化,2023,25(5):1821-1827.
[12] 王一萌,王焕霞.美托洛尔干预急性心肌缺血病人前后QT离散度的对比分析[J].中西医结合心脑血管病杂志,2020,18(3):503-505.